2024 ICD-10-CM Diagnosis Code T50.995S

Adverse effect of other drugs, medicaments and biological substances, sequela

ICD-10-CM Code:
T50.995S
ICD-10 Code for:
Adverse effect of drug/meds/biol subst, sequela
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances
        (T50)

T50.995S is a billable diagnosis code used to specify a medical diagnosis of adverse effect of other drugs, medicaments and biological substances, sequela. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

T50.995S is a sequela code, includes a 7th character and should be used for complications that arise as a direct result of a condition like adverse effect of other drugs medicaments and biological substances. According to ICD-10-CM Guidelines a "sequela" code should be used for chronic or residual conditions that are complications of an initial acute disease, illness or injury. The most common sequela is pain. Usually, two diagnosis codes are needed when reporting sequela. The first code describes the nature of the sequela while the second code describes the sequela or late effect.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Acitretin adverse reaction
  • Adverse cutaneous reaction to herbal medicine
  • Adverse cutaneous reaction to homeopathic medicine
  • Adverse reaction caused by bisphosphonate
  • Adverse reaction caused by bisphosphonate
  • Adverse reaction caused by bisphosphonate
  • Adverse reaction caused by canagliflozin
  • Adverse reaction caused by dapagliflozin
  • Adverse reaction caused by empagliflozin
  • Adverse reaction caused by ertugliflozin
  • Adverse reaction to allergenic extract
  • Adverse reaction to aluminum and/or aluminum compound
  • Adverse reaction to bile acid and/or bile acid derivative
  • Adverse reaction to bile acid and/or bile acid derivative
  • Adverse reaction to bone resorption inhibitor
  • Adverse reaction to bone resorption inhibitor
  • Adverse reaction to calcium carbonate and/or etidronic acid
  • Adverse reaction to calcium carbonate and/or etidronic acid
  • Adverse reaction to chenodeoxycholic acid and/or ursodeoxycholic acid
  • Adverse reaction to chenodeoxycholic acid and/or ursodeoxycholic acid
  • Adverse reaction to clodronic acid
  • Adverse reaction to drug primarily acting on nutrition
  • Adverse reaction to etidronic acid
  • Adverse reaction to fatty acid
  • Adverse reaction to Fuller's earth
  • Adverse reaction to glycol
  • Adverse reaction to hyaluronic acid
  • Adverse reaction to inorganic chemical
  • Adverse reaction to oil
  • Adverse reaction to pamidronic acid
  • Adverse reaction to parathyroid hormone and/or parathyroid hormone derivative
  • Adverse reaction to phosphodiesterase 5 inhibitor
  • Adverse reaction to substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action
  • Aldehyde dehydrogenase inhibitor adverse reaction
  • Anionic surfactant adverse reaction
  • Antidotes for pesticides adverse reaction
  • Bufexamac adverse reaction
  • Bulk-forming laxative adverse reaction
  • Calcitonin adverse reaction
  • Calcitonin adverse reaction
  • Calcium polystyrene sulfonate adverse reaction
  • Calcium regulating agent adverse reaction
  • Calcium regulating hormone adverse reaction
  • Calcium regulating hormone adverse reaction
  • Calcium regulating hormone adverse reaction
  • Calcium regulating hormone adverse reaction
  • Carbomer-940 adverse reaction
  • Cation exchange resin adverse reaction
  • Cellulose-derived viscosity modifier adverse reaction
  • Chorea caused by dopamine receptor antagonist
  • Citrate adverse reaction
  • Colchicum alkaloid adverse reaction
  • Collagen adverse reaction
  • Colony stimulating factors adverse reaction
  • Dimethyl-ether propane adverse reaction
  • Disinfectants and cleansers adverse reaction
  • Drug reaction with eosinophilia and systemic symptoms
  • Drug reaction with eosinophilia and systemic symptoms caused by strontium ranelate
  • Drug-induced uveitis
  • Ear wax removal preparation adverse reaction
  • Enbucrilate adverse reaction
  • Ergoline drug adverse reaction
  • Etretinate adverse reaction
  • Filgrastim adverse reaction
  • Fixed oil adverse reaction
  • Fluoride adverse reaction
  • Gold nephropathy
  • Hemostatic adverse reaction
  • Herbal medicine adverse reaction
  • Homeopathic medicine adverse reaction
  • Immunostimulant adverse reaction
  • Inositol adverse reaction
  • Ion exchange resin adverse reaction
  • Isotretinoin adverse reaction
  • Lenograstim adverse reaction
  • Methyl methacrylate embolism
  • Molgramostim adverse reaction
  • Nicotine adverse reaction
  • Non-ionic surfactant adverse reaction
  • Oral leukoplakia caused by sanguinarine
  • Osteonecrosis of jaw
  • Osteonecrosis of jaw caused by drug
  • Osteonecrosis of jaw due to bisphosphonate
  • Pamidronic acid-induced uveitis
  • p-di-Isobutylphenoxypolyethoxyethanol adverse reaction
  • Phosphodiesterase inhibitor adverse reaction
  • Radiopharmaceutical adverse reaction
  • Retinoid adverse reaction
  • Retinoid adverse reaction
  • Retinoid adverse reaction
  • Retinopathy caused by canthaxanthin
  • Salmon calcitonin adverse reaction
  • Sodium fluoride adverse reaction
  • Surgical tissue adhesive adverse reaction
  • Terpenes adverse reaction
  • Urinary disorder monitoring status
  • Urinary drug side effect
  • Ursodeoxycholic acid adverse reaction
  • Viscosity modifier adverse reaction
  • Xanthine oxidase inhibitor adverse reaction

Clinical Classification

Clinical Information

  • Acitretin

    an oral retinoid effective in the treatment of psoriasis. it is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
  • Arginine

    an essential amino acid that is physiologically active in the l-form.
  • Arginine Kinase

    an enzyme that catalyzes the phosphorylation of the guanidine nitrogen of arginine in the presence of atp and a divalent cation with formation of phosphorylarginine and adp. ec 2.7.3.3.
  • Arginine Vasopressin

    the predominant form of mammalian antidiuretic hormone. it is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. arg-vasopressin is used to treat diabetes insipidus or to improve vasomotor tone and blood pressure.
  • Arginine-tRNA Ligase

    an enzyme that activates arginine with its specific transfer rna. ec 6.1.1.19.
  • Carboxypeptidase B2

    a carboxypeptidase that removes c-terminal lysine or arginine from peptides and proteins. carboxypeptidase b2 (cpb2) is released into the circulation as a proenzyme which is activated by the thrombin-thrombomodulin complex. activated cpb2 is involved in modulating a variety of processes by cleaving and inactivating various circulating proteins and peptides that are its substrates including fibrin; kinins; and anaphylatoxins.
  • Deamino Arginine Vasopressin

    a synthetic analog of the pituitary hormone, arginine vasopressin. its action is mediated by the vasopressin receptor v2. it has prolonged antidiuretic activity, but little pressor effects. it also modulates levels of circulating factor viii and von willebrand factor.
  • Gingipain Cysteine Endopeptidases

    cysteine endoproteinases, from periodontal pathogen porphyromonas gingivalis, acting as virulence factors associated with periodontitis. they are produced as pre-proproteins which mature into arginine and lysine specific endopeptidases.
  • Histone Demethylases

    enzymes that catalyse the removal of methyl groups from lysine or arginine residues found on histones. many histone demethylases generally function through an oxidoreductive mechanism.
  • Hyperargininemia

    a rare autosomal recessive disorder of the urea cycle. it is caused by a deficiency of the hepatic enzyme arginase. arginine is elevated in the blood and cerebrospinal fluid, and periodic hyperammonemia may occur. disease onset is usually in infancy or early childhood. clinical manifestations include seizures, microcephaly, progressive mental impairment, hypotonia, ataxia, spastic diplegia, and quadriparesis. (from hum genet 1993 mar;91(1):1-5; menkes, textbook of child neurology, 5th ed, p51)
  • omega-N-Methylarginine

    a competitive inhibitor of nitric oxide synthetase.
  • Protein-Arginine N-Methyltransferases

    enzymes that catalyze the methylation of arginine residues of proteins to yield n-mono- and n,n-dimethylarginine. this enzyme is found in many organs, primarily brain and spleen.
  • Receptors, Vasopressin

    specific molecular sites or proteins on or in cells to which vasopressins bind or interact in order to modify the function of the cells. two types of vasopressin receptor exist, the v1 receptor in the vascular smooth muscle and the v2 receptor in the kidneys. the v1 receptor can be subdivided into v1a and v1b (formerly v3) receptors.
  • RNA, Transfer, Arg

    a transfer rna which is specific for carrying arginine to sites on the ribosomes in preparation for protein synthesis.
  • Vasotocin

    a nonapeptide that contains the ring of oxytocin and the side chain of arg-vasopressin with the latter determining the specific recognition of hormone receptors. vasotocin is the non-mammalian vasopressin-like hormone or antidiuretic hormone regulating water and salt metabolism.
  • Calcitonin

    a peptide hormone that lowers calcium concentration in the blood. in humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
  • Calcitonin Gene-Related Peptide

    a 37-amino acid peptide derived from the calcitonin gene. it occurs as a result of alternative processing of mrna from the calcitonin gene. the neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue. the peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. in particular, it is a potent endogenous vasodilator.
  • Calcitonin Gene-Related Peptide Receptor Antagonists

    pharmacologic agents that block nociceptive pain signaling from calcitonin gene-related peptide receptors. they may be useful for the treatment of pain associated with migraine disorders and osteoarthritis.
  • Calcitonin Receptor-Like Protein

    a receptor protein that is associated with receptor activity-modifying proteins. when bound to receptor activity-modifying protein 1 it forms the calcitonin gene-related receptor. when bound to receptor activity-modifying protein 2 or receptor activity-modifying protein 3 it forms the adrenomedullin receptor.
  • Procalcitonin

    a peptide prohormone precursor of calcitonin. it is normally present at low levels in serum, but is released into the bloodstream, primarily from neuroendocrine cells in the lungs and intestines, in response to inflammation and bacterial infections. it is a diagnostic marker for bacteremia.
  • Receptor Activity-Modifying Protein 1

    a receptor activity-modifying protein that is a subunit of specific g-protein coupled receptors. the calcitonin gene-related peptide receptor is formed from a dimer of this protein and calcitonin receptor-like protein, while an isoform of the islet amyloid polypeptide receptor is formed from this protein dimerizing with the calcitonin receptor.
  • Receptor Activity-Modifying Protein 2

    a receptor activity-modifying protein that heterodimerizes with calcitonin receptor-like protein to form the adrenomedullin receptor. in addition, an isoform of the islet amyloid polypeptide receptor is formed from this protein dimerizing with the calcitonin receptor.
  • Receptor Activity-Modifying Protein 3

    a receptor activity-modifying protein that heterodimerizes with calcitonin receptor-like protein to form the adrenomedullin receptor. in addition, an isoform of the islet amyloid polypeptide receptor is formed from this protein dimerizing with the calcitonin receptor.
  • Receptors, Calcitonin

    cell surface proteins that bind calcitonin and trigger intracellular changes which influence the behavior of cells. calcitonin receptors outside the nervous system mediate the role of calcitonin in calcium homeostasis. the role of calcitonin receptors in the brain is not well understood.
  • Receptors, Calcitonin Gene-Related Peptide

    cell surface proteins that bind calcitonin gene-related peptide with high affinity and trigger intracellular changes which influence the behavior of cells. cgrp receptors are present in both the central nervous system and the periphery. they are formed via the heterodimerization of the calcitonin receptor-like protein and receptor activity-modifying protein 1.
  • Canthaxanthin

    a trans-carotenoid pigment widely distributed in nature. the compound is used as an oral suntanning agent and as a food and drug coloring agent. oral ingestion of the compound causes canthaxanthin retinopathy.
  • Cetomacrogol

    non-ionic surfactant of the polyethylene glycol family. it is used as a solubilizer and emulsifying agent in foods, cosmetics, and pharmaceuticals, often as an ointment base, and also as a research tool.
  • Chlorophyll

    porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.
  • Chlorophyll A

    a form of chlorophyll that absorbs light in the violet to red spectrum (approximately 400-700 nm wavelength range) and reflects green light (500-570 nm wavelength), which imparts the characteristic green color to land plants. it is essential for oxygenic photosynthesis.
  • Chlorophyll Binding Proteins

    a large family of proteins that have been traditionally classified as the light-harvesting proteins of the photosynthetic reaction complex. chlorophyll binding proteins are also found in non-photosynthetic settings where they may play a photoprotective role in response to light stress.
  • Chlorophyllides

    products of the hydrolysis of chlorophylls in which the phytic acid side chain has been removed and the carboxylic acids saponified.
  • Light-Harvesting Protein Complexes

    complexes containing chlorophyll and other photosensitive molecules. they serve to capture energy in the form of photons and are generally found as components of the photosystem i protein complex or the photosystem ii protein complex.
  • Clodronic Acid

    a diphosphonate which affects calcium metabolism. it inhibits bone resorption and soft tissue calcification.
  • 1-Acylglycerol-3-Phosphate O-Acyltransferase

    an enzyme that catalyzes the acyl group transfer of acyl coa to 1-acyl-sn-glycerol 3-phosphate to generate 1,2-diacyl-sn-glycerol 3-phosphate. this enzyme has alpha, beta, gamma, delta and epsilon subunits.
  • Acetyl Coenzyme A

    acetyl coa participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. it also acts as a biological acetylating agent.
  • Acyl Coenzyme A

    s-acyl coenzyme a. fatty acid coenzyme a derivatives that are involved in the biosynthesis and oxidation of fatty acids as well as in ceramide formation.
  • Coenzyme A

  • Coenzyme A Ligases

    enzymes that catalyze the formation of acyl-coa derivatives. ec 6.2.1.
  • Coenzyme A-Transferases

    enzymes which transfer coenzyme a moieties from acyl- or acetyl-coa to various carboxylic acceptors forming a thiol ester. enzymes in this group are instrumental in ketone body metabolism and utilization of acetoacetate in mitochondria. ec 2.8.3.
  • Malonyl Coenzyme A

    a coenzyme a derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.
  • Palmitoyl Coenzyme A

    a fatty acid coenzyme derivative which plays a key role in fatty acid oxidation and biosynthesis.
  • Arthritis, Experimental

    arthritis that is induced in experimental animals. immunological methods and infectious agents can be used to develop experimental arthritis models. these methods include injections of stimulators of the immune response, such as an adjuvant (adjuvants, immunologic) or collagen.
  • Colitis, Collagenous

    a subtype of microscopic colitis, characterized by chronic watery diarrhea of unknown origin, a normal colonoscopy but abnormal histopathology on biopsy. microscopic examination of biopsy samples taken from the colon show larger-than-normal band of subepithelial collagen.
  • Collagen

    a polypeptide substance comprising about one third of the total protein in mammalian organisms. it is the main constituent of skin; connective tissue; and the organic substance of bones (bone and bones) and teeth (tooth).
  • Collagen Diseases

    historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. this classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (from cecil textbook of medicine, 19th ed, p1494)
  • Collagen Type I

    the most common form of fibrillar collagen. it is a major constituent of bone (bone and bones) and skin and consists of a heterotrimer of two alpha1(i) and one alpha2(i) chains.
  • Collagen Type I, alpha 1 Chain

    a fibrillar collagen found predominantly in bone and skin.
  • Collagen Type II

    a fibrillar collagen found predominantly in cartilage and vitreous humor. it consists of three identical alpha1(ii) chains.
  • Collagen Type III

    a fibrillar collagen consisting of three identical alpha1(iii) chains that is widely distributed in many tissues containing collagen type i. it is particularly abundant in blood vessels and may play a role in tissues with elastic characteristics.
  • Collagen Type IV

    a non-fibrillar collagen found in the structure of basement membrane. collagen type iv molecules assemble to form a sheet-like network which is involved in maintaining the structural integrity of basement membranes. the predominant form of the protein is comprised of two alpha1(iv) subunits and one alpha2(iv) subunit, however, at least six different alpha subunits can be incorporated into the heterotrimer.
  • Collagen Type IX

    a fibril-associated collagen usually found crosslinked to the surface of collagen type ii fibrils. it is a heterotrimer containing alpha1(ix), alpha2(ix) and alpha3(ix) subunits.
  • Collagen Type V

    a fibrillar collagen found widely distributed as a minor component in tissues that contain collagen type i and collagen type iii. it is a heterotrimeric molecule composed of alpha1(v), alpha2(v) and alpha3(v) subunits. several forms of collagen type v exist depending upon the composition of the subunits that form the trimer.
  • Collagen Type VI

    a non-fibrillar collagen that forms a network of microfibrils within the extracellular matrix of connective tissue. the alpha subunits of collagen type vi assemble into antiparallel, overlapping dimers which then align to form tetramers.
  • Collagen Type VII

    a non-fibrillar collagen involved in anchoring the epidermal basement membrane to underlying tissue. it is a homotrimer comprised of c-terminal and n-terminal globular domains connected by a central triple-helical region.
  • Collagen Type VIII

    a non-fibrillar collagen originally found in descemet membrane. it is expressed in endothelial cell layers and in tissues undergoing active remodeling. it is heterotrimer comprised of alpha1(viii) and alpha2(viii) chains.
  • Collagen Type X

    a non-fibrillar collagen found primarily in terminally differentiated hypertrophic chondrocytes. it is a homotrimer of three identical alpha1(x) subunits.
  • Collagen Type XI

    a fibrillar collagen found primarily in interstitial cartilage. collagen type xi is heterotrimer containing alpha1(xi), alpha2(xi) and alpha3(xi) subunits.
  • Collagen Type XII

    a fibril-associated collagen found in many tissues bearing high tensile stress, such as tendons and ligaments. it is comprised of a trimer of three identical alpha1(xii) chains.
  • Collagen Type XIII

    a non-fibrillar collagen found as a ubiquitously expressed membrane- associated protein. type xiii collagen contains both collagenous and non-collagenous domains along with a transmembrane domain within its n-terminal region.
  • Collagen Type XVIII

    a non-fibrillar collagen found in basement membrane. the c-terminal end of the alpha1 chain of collagen type xviii contains the endostatin peptide, which can be released by proteolytic cleavage.
  • Collagenases

    enzymes that catalyze the degradation of collagen by acting on the peptide bonds.
  • Collagenous Sprue

    a malabsorption syndrome characterized by collagenous mucosal lesions of the small intestine, atrophy of microvilli, severe malabsorption, diarrhea, and malnutrition often refractory to a gluten-free diet.
  • Collectins

    a class of c-type lectins that target the carbohydrate structures found on invading pathogens. binding of collectins to microorganisms results in their agglutination and enhanced clearance. collectins form trimers that may assemble into larger oligomers. each collectin polypeptide chain consists of four regions: a relatively short n-terminal region, a collagen-like region, an alpha-helical coiled-coil region, and carbohydrate-binding region.
  • Corneal Cross-Linking

    an ophthalmic treatment used to prevent weakening or bulging of the cornea in corneal ectasia, e.g., post-lasik ectasia, keratoconus and pellucid marginal corneal degeneration. it uses uv-a and riboflavin to crosslink and strengthen collagen fibers within the cornea.
  • Fibril-Associated Collagens

    a family of non-fibrillar collagens that interact with fibrillar collagens. they contain short triple helical domains interrupted by short non-helical domains and do not form into collagen fibrils.
  • Fibrillar Collagens

    a family of structurally related collagens that form the characteristic collagen fibril bundles seen in connective tissue.
  • Fibroma, Desmoplastic

    an extremely rare bone tumor characterized by abundant collagen formation and a fibrous stroma, without evidence of mitosis or pleomorphism. it appears on x-rays as an osteolytic lesion with well-defined margins and must be differentiated from primary fibrosarcoma of bone. (devita jr et al., cancer: principles & practice of oncology, 3d ed, p1441)
  • Matrix Metalloproteinase 13

    a secreted matrix metalloproteinase that plays a physiological role in the degradation of extracellular matrix found in skeletal tissues. it is synthesized as an inactive precursor that is activated by the proteolytic cleavage of its n-terminal propeptide.
  • Matrix Metalloproteinase 8

    a member of the matrix metalloproteinases that cleaves triple-helical collagen types i, ii, and iii.
  • Matrix Metalloproteinase Inhibitors

    compounds that inhibit the enzyme activity or activation of matrix metalloproteinases.
  • Microbial Collagenase

    a metalloproteinase which degrades helical regions of native collagen to small fragments. preferred cleavage is -gly in the sequence -pro-xaa-gly-pro-. six forms (or 2 classes) have been isolated from clostridium histolyticum that are immunologically cross-reactive but possess different sequences and different specificities. other variants have been isolated from bacillus cereus, empedobacter collagenolyticum, pseudomonas marinoglutinosa, and species of vibrio and streptomyces. ec 3.4.24.3.
  • Non-Fibrillar Collagens

    a family of structurally-related short-chain collagens that do not form large fibril bundles.
  • Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase

    a mixed-function oxygenase that catalyzes the hydroxylation of peptidyllysine, usually in protocollagen, to peptidylhydroxylysine. the enzyme utilizes molecular oxygen with concomitant oxidative decarboxylation of the cosubstrate 2-oxoglutarate to succinate. ec 1.14.11.4.
  • Protein-Lysine 6-Oxidase

    an enzyme oxidizing peptidyl-lysyl-peptide in the presence of water & molecular oxygen to yield peptidyl-allysyl-peptide plus ammonia & hydrogen peroxide. ec 1.4.3.13.
  • Punctal Plugs

    small devices that are inserted into the tear ducts (nasolacrimal ducts). they are used to block the drainage of tears for the treatment of dry eye syndromes.
  • Receptors, Collagen

    cell surface receptors that modulate signal transduction between cells and the extracellular matrix. they are found in many cell types and are involved in the maintenance and regulation of cell shape and behavior, including platelet activation and aggregation, through many different signaling pathways and differences in their affinities for collagen isoforms. collagen receptors include discoidin domain receptors; integrins; and gp6, one of the platelet membrane glycoproteins.
  • Etretinate

    an oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. the compound may be teratogenic.
  • CDP-Diacylglycerol-Inositol 3-Phosphatidyltransferase

    an enzyme that catalyzes the formation of phosphatidylinositol and cmp from cdp-diacylglycerol and myoinositol.
  • Glycerophosphoinositol Inositolphosphodiesterase

    a phosphoric diester hydrolase with specificity for the cleavage of glycerol from 1-(sn-glycero-3-phospho)-1d-myo-inositol. it also has specificity for hydrolysis of the cyclic phosphate bond in inositol 1,2-cyclic phosphate
  • Inositol

    an isomer of glucose that has traditionally been considered to be a b vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (from martindale, the extra pharmacopoeia, 30th ed, p1379) inositol phospholipids are important in signal transduction.
  • Inositol 1,4,5-Trisphosphate

    intracellular messenger formed by the action of phospholipase c on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. these calcium ions stimulate the activity of b kinase or calmodulin.
  • Inositol 1,4,5-Trisphosphate Receptors

    intracellular receptors that bind to inositol 1,4,5-trisphosphate and play an important role in its intracellular signaling. inositol 1,4,5-trisphosphate receptors are calcium channels that release calcium in response to increased levels of inositol 1,4,5-trisphosphate in the cytoplasm.
  • Inositol Oxygenase

    a non-heme iron enzyme that catalyzes the conversion of myoinositol to d-glucuronic acid. the reaction is the first committed step in myoinositol catabolic pathway. this enzyme was formerly characterized as ec 1.13.1.11 and 1.99.2.6.
  • Inositol Phosphates

    phosphoric acid esters of inositol. they include mono- and polyphosphoric acid esters, with the exception of inositol hexaphosphate which is phytic acid.
  • Inositol Polyphosphate 5-Phosphatases

    phosphoinositide phosphatases that catalyze the removal of the 5' phosphate from inositol 1,4,5-trisphosphate or myo-inositol 1,3,4,5-tetrakisphosphate, resulting in inositol 1,4-bisphosphate and phosphate. they have important functions in the metabolism of inositol phosphates and inositol 1,4,5-trisphosphate signaling pathways such as calcium signaling.
  • Myo-Inositol-1-Phosphate Synthase

    an enzyme that catalyzes the formation of myo-inositol-1-phosphate from glucose-6-phosphate in the presence of nad. ec 5.5.1.4.
  • Phosphatidylinositol Phosphates

    phosphatidylinositols in which one or more alcohol group of the inositol has been substituted with a phosphate group.
  • Phosphatidylinositols

    derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to the hexahydroxy alcohol, myo-inositol. complete hydrolysis yields 1 mole of glycerol, phosphoric acid, myo-inositol, and 2 moles of fatty acids.
  • Phosphoinositide Phospholipase C

    a type c phospholipase with specificity towards phosphatidylinositols that contain inositol 1,4,5-trisphosphate. many of the enzymes listed under this classification are involved in intracellular signaling.
  • Phytic Acid

    complexing agent for removal of traces of heavy metal ions. it acts also as a hypocalcemic agent.
  • Isotretinoin

    a topical dermatologic agent that is used in the treatment of acne vulgaris and several other skin diseases. the drug has teratogenic and other adverse effects.
  • 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase

    an enzyme that catalyzes the formation of methionine by transfer of a methyl group from 5-methyltetrahydrofolate to homocysteine. it requires a cobamide coenzyme. the enzyme can act on mono- or triglutamate derivatives. ec 2.1.1.13.
  • Enkephalin, Methionine

    one of the endogenous pentapeptides with morphine-like activity. it differs from leu-enkephalin by the amino acid methionine in position 5. its first four amino acid sequence is identical to the tetrapeptide sequence at the n-terminal of beta-endorphin.
  • Guanidinoacetate N-Methyltransferase

    this enzyme catalyzes the last step of creatine biosynthesis by catalyzing the methylation of guanidinoacetate to creatine.
  • Methionine

    a sulfur-containing essential l-amino acid that is important in many body functions.
  • Methionine Adenosyltransferase

    an enzyme that catalyzes the synthesis of s-adenosylmethionine from methionine and atp. ec 2.5.1.6.
  • Methionine Sulfoxide Reductases

    reductases that catalyze the reaction of peptide-l-methionine -s-oxide + thioredoxin to produce peptide-l-methionine + thioredoxin disulfide + h(2)o.
  • Methionine Sulfoximine

  • Methionine-tRNA Ligase

    an enzyme that activates methionine with its specific transfer rna. ec 6.1.1.10.
  • Methionyl Aminopeptidases

    aminopeptidases that remove methionine from the amino-terminus of a peptide chain, such as the initiator methionine found on nascent peptide chains.
  • Peptide PHI

    a 27-amino acid peptide with histidine at the n-terminal and isoleucine amide at the c-terminal. the exact amino acid composition of the peptide is species dependent. the peptide is secreted in the intestine, but is found in the nervous system, many organs, and in the majority of peripheral tissues. it has a wide range of biological actions, affecting the cardiovascular, gastrointestinal, respiratory, and central nervous systems.
  • Racemethionine

    a preparation of methionine that includes a mixture of d-methionine and l-methionine isomers.
  • RNA, Transfer, Met

    a transfer rna which is specific for carrying methionine to sites on the ribosomes. during initiation of protein synthesis, trna(f)met in prokaryotic cells and trna(i)met in eukaryotic cells binds to the start codon (codon, initiator).
  • Vitamin U

    a vitamin found in green vegetables. it is used in the treatment of peptic ulcers, colitis, and gastritis and has an effect on secretory, acid-forming, and enzymatic functions of the intestinal tract.
  • Methoxsalen

    a naturally occurring furocoumarin compound found in several species of plants, including psoralea corylifolia. it is a photoactive substance that forms dna adducts in the presence of ultraviolet a irradiation.
  • Arylalkylamine N-Acetyltransferase

    an acetyltransferase with specificity towards the amine group of aromatic alkylamines (arylalkylamines) such as serotonin. this enzyme is also referred to as serotonin acetylase despite the fact that serotonin acetylation can also occur through the action of broad specificity acetyltransferases such as arylamine n-acetyltransferase.
  • Enterochromaffin Cells

    a subtype of enteroendocrine cells found in the gastrointestinal mucosa, particularly in the glands of pyloric antrum; duodenum; and ileum. these cells secrete mainly serotonin and some neuropeptides. their secretory granules stain readily with silver (argentaffin stain).
  • Receptor, Serotonin, 5-HT1A

    a serotonin receptor subtype found distributed through the central nervous system where they are involved in neuroendocrine regulation of acth secretion. the fact that this serotonin receptor subtype is particularly sensitive to serotonin receptor agonists such as buspirone suggests its role in the modulation of anxiety and depression.
  • Receptor, Serotonin, 5-HT1B

    a serotonin receptor subtype found at high levels in the basal ganglia and the frontal cortex. it plays a role as a terminal autoreceptor that regulates the rate of serotonin release from nerve endings. this serotonin receptor subtype is closely related to and has similar drug binding properties as the 5-ht1d receptor. it is particularly sensitive to the agonist sumatriptan and may be involved in mediating the drug's antimigraine effect.
  • Receptor, Serotonin, 5-HT1D

    a serotonin receptor subtype that is localized to the caudate nucleus; putamen; the nucleus accumbens; the hippocampus, and the raphe nuclei. it plays a role as a terminal autoreceptor that regulates the rate of serotonin release from nerve endings. this serotonin receptor subtype is closely related to and has similar drug binding properties as the 5-ht1b receptor, but is expressed at low levels. it is particularly sensitive to the agonist sumatriptan and may be involved in mediating the drug's antimigrane effect.
  • Receptor, Serotonin, 5-HT2A

    a serotonin receptor subtype found widely distributed in peripheral tissues where it mediates the contractile responses of variety of tissues that contain smooth muscle. selective 5-ht2a receptor antagonists include ketanserin. the 5-ht2a subtype is also located in basal ganglia and cerebral cortex of the brain where it mediates the effects of hallucinogens such as lsd.
  • Receptor, Serotonin, 5-HT2B

    a serotonin receptor subtype found in the brain; heart; lungs; placenta and digestive system organs. a number of functions have been attributed to the action of the 5-ht2b receptor including the development of cardiac myocytes (myocytes, cardiac) and the contraction of smooth muscle.
  • Receptor, Serotonin, 5-HT2C

    a serotonin receptor subtype found primarily in the central nervous system and the choroid plexus. this receptor subtype is believed to mediate the anorectic action of serotonin, while selective antagonists of the 5-ht2c receptor appear to induce anxiety. several isoforms of this receptor subtype exist, due to adenine deaminase editing of the receptor mrna.
  • Receptors, Serotonin

    cell-surface proteins that bind serotonin and trigger intracellular changes which influence the behavior of cells. several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.
  • Receptors, Serotonin, 5-HT1

    a subclass of g-protein coupled serotonin receptors that couple preferentially to gi-go g-proteins resulting in decreased intracellular cyclic amp levels.
  • Receptors, Serotonin, 5-HT2

    a subclass of g-protein coupled serotonin receptors that couple preferentially to the gq-g11 g-proteins resulting in increased intracellular levels of inositol phosphates and free calcium.
  • Receptors, Serotonin, 5-HT3

    a subclass of serotonin receptors that form cation channels and mediate signal transduction by depolarizing the cell membrane. the cation channels are formed from 5 receptor subunits. when stimulated the receptors allow the selective passage of sodium; potassium; and calcium.
  • Receptors, Serotonin, 5-HT4

    a subtype of g-protein-coupled serotonin receptors that preferentially couple to gs stimulatory g-proteins resulting in increased intracellular cyclic amp. several isoforms of the receptor exist due to alternative splicing of its mrna.
  • Selective Serotonin Reuptake Inhibitors

    compounds that specifically inhibit the reuptake of serotonin in the brain.
  • Serotonergic Neurons

    neurons whose primary neurotransmitter is serotonin.
  • Serotonin

    a biochemical messenger and regulator, synthesized from the essential amino acid l-tryptophan. in humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. multiple receptor families (receptors, serotonin) explain the broad physiological actions and distribution of this biochemical mediator.
  • Serotonin 5-HT1 Receptor Agonists

    endogenous compounds and drugs that specifically stimulate serotonin 5-ht1 receptors. included under this heading are agonists for one or more of the specific 5-ht1 receptor subtypes.
  • Serotonin 5-HT1 Receptor Antagonists

    drugs that bind to but do not activate serotonin 5-ht1 receptors, thereby blocking the actions of serotonin 5-ht1 receptor agonists. included under this heading are antagonists for one or more of the specific 5-ht1 receptor subtypes.
  • Serotonin 5-HT2 Receptor Agonists

    endogenous compounds and drugs that specifically stimulate serotonin 5-ht2 receptors. included under this heading are agonists for one or more of the specific 5-ht2 receptor subtypes.
  • Serotonin 5-HT2 Receptor Antagonists

    drugs that bind to but do not activate serotonin 5-ht2 receptors, thereby blocking the actions of serotonin or serotonin 5-ht2 receptor agonists. included under this heading are antagonists for one or more specific 5-ht2 receptor subtypes.
  • Serotonin 5-HT3 Receptor Agonists

    endogenous compounds and drugs that specifically stimulate serotonin 5-ht3 receptors.
  • Serotonin 5-HT3 Receptor Antagonists

    drugs that bind to but do not activate serotonin 5-ht3 receptors, thereby blocking the actions of serotonin or serotonin 5-ht3 receptor agonists.
  • Serotonin 5-HT4 Receptor Agonists

    endogenous compounds and drugs that specifically stimulate serotonin 5-ht4 receptors.
  • Serotonin 5-HT4 Receptor Antagonists

    drugs that bind to but do not activate serotonin 5-ht4 receptors, thereby blocking the actions of serotonin or serotonin receptor agonists.
  • Serotonin Agents

    drugs used for their effects on serotonergic systems. among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons.
  • Serotonin and Noradrenaline Reuptake Inhibitors

    drugs that selectively block or suppress the plasma membrane transport of serotonin and noradrenaline into axon terminals and are used as antidepressive agents.
  • Serotonin Antagonists

    drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin receptor agonists.
  • Serotonin Plasma Membrane Transport Proteins

    sodium chloride-dependent neurotransmitter symporters located primarily on the plasma membrane of serotonergic neurons. they are different than serotonin receptors, which signal cellular responses to serotonin. they remove serotonin from the extracellular space by high affinity reuptake into presynaptic terminals. regulates signal amplitude and duration at serotonergic synapses and is the site of action of the selective serotonin reuptake inhibitors.
  • Serotonin Receptor Agonists

    endogenous compounds and drugs that bind to and activate serotonin receptors. many serotonin receptor agonists are used as antidepressants; anxiolytics; and in the treatment of migraine disorders.
  • Serotonin Syndrome

    an adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. it is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the cns at the serotonin 1a receptor.
  • Silymarin

    a mixture of flavonoids extracted from seeds of the milk thistle, silybum marianum. it consists primarily of silybin and its isomers, silicristin and silidianin. silymarin displays antioxidant and membrane stabilizing activity. it protects various tissues and organs against chemical injury, and shows potential as an antihepatoxic agent.
  • Thioctic Acid

    an octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. it is biosynthesized by cleavage of linoleic acid and is a coenzyme of oxoglutarate dehydrogenase (ketoglutarate dehydrogenase complex). it is used in dietary supplements.
  • Tiopronin

    sulfhydryl acylated derivative of glycine.
  • Karaya Gum

    polysaccharide gum from sterculia urens (sterculia). it is used as a suspending or stabilizing agent in foods, cosmetics and pharmaceuticals; a bulk-forming laxative; a surgical lubricant and adhesive; and in the treatment of skin ulcers.
  • Tragacanth

    powdered exudate from astragalus gummifer and related plants. it forms gelatinous mass in water. tragacanth is used as suspending agent, excipient or emulsifier in foods, cosmetics and pharmaceuticals. it has also been used as a bulk-forming laxative.
  • Ursodeoxycholic Acid

    an epimer of chenodeoxycholic acid. it is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. its administration changes the composition of bile and may dissolve gallstones. it is used as a cholagogue and choleretic.

Coding Guidelines

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances (T50). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Present on Admission (POA)

T50.995S is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T50.995S to ICD-9-CM

  • ICD-9-CM Code: 909.5 - Lte efct advrs efct drug
    Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.
  • ICD-9-CM Code: E947.8 - Adv eff medicinal NEC
    Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.

Table of Drugs and Chemicals

The parent code T50.995 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
Acetohydroxamic acidT50.991T50.992T50.993T50.994T50.995T50.996
AcitretinT50.991T50.992T50.993T50.994T50.995T50.996
ArginineT50.991T50.992T50.993T50.994T50.995T50.996
Arginine
  »glutamate
T50.991T50.992T50.993T50.994T50.995T50.996
Baking sodaT50.991T50.992T50.993T50.994T50.995T50.996
BergaptenT50.991T50.992T50.993T50.994T50.995T50.996
BHAT50.991T50.992T50.993T50.994T50.995T50.996
Bromophenol blue reagentT50.991T50.992T50.993T50.994T50.995T50.996
Butylated hydroxy-anisoleT50.991T50.992T50.993T50.994T50.995T50.996
CalcitoninT50.991T50.992T50.993T50.994T50.995T50.996
Calculus-dissolving drugT50.991T50.992T50.993T50.994T50.995T50.996
CanthaxanthinT50.991T50.992T50.993T50.994T50.995T50.996
CetomacrogolT50.991T50.992T50.993T50.994T50.995T50.996
ChlorophyllT50.991T50.992T50.993T50.994T50.995T50.996
CianidanolT50.991T50.992T50.993T50.994T50.995T50.996
Clodronic acidT50.991T50.992T50.993T50.994T50.995T50.996
Coenzyme AT50.991T50.992T50.993T50.994T50.995T50.996
Cogalactoiso-meraseT50.991T50.992T50.993T50.994T50.995T50.996
CollagenT50.991T50.992T50.993T50.994T50.995T50.996
Colorant [See Also: Dye]T50.991T50.992T50.993T50.994T50.995T50.996
CyclamateT50.991T50.992T50.993T50.994T50.995T50.996
Deanol (aceglumate)T50.991T50.992T50.993T50.994T50.995T50.996
ElcatoninT50.991T50.992T50.993T50.994T50.995T50.996
EpomediolT50.991T50.992T50.993T50.994T50.995T50.996
EtidronateT50.991T50.992T50.993T50.994T50.995T50.996
Etidronic acid (disodium salt)T50.991T50.992T50.993T50.994T50.995T50.996
EtretinateT50.991T50.992T50.993T50.994T50.995T50.996
Fat suspension, intravenousT50.991T50.992T50.993T50.994T50.995T50.996
Gallium citrateT50.991T50.992T50.993T50.994T50.995T50.996
GelsemineT50.991T50.992T50.993T50.994T50.995T50.996
Gluconic acidT50.991T50.992T50.993T50.994T50.995T50.996
GlycerophosphateT50.991T50.992T50.993T50.994T50.995T50.996
Guaiac reagentT50.991T50.992T50.993T50.994T50.995T50.996
InositolT50.991T50.992T50.993T50.994T50.995T50.996
Inositol
  »nicotinate
T50.991T50.992T50.993T50.994T50.995T50.996
IntravenousT50.991T50.992T50.993T50.994T50.995T50.996
Intravenous
  »amino acids
T50.991T50.992T50.993T50.994T50.995T50.996
Intravenous
  »fat suspension
T50.991T50.992T50.993T50.994T50.995T50.996
IsotretinoinT50.991T50.992T50.993T50.994T50.995T50.996
LevocarnitineT50.991T50.992T50.993T50.994T50.995T50.996
LevoglutamideT50.991T50.992T50.993T50.994T50.995T50.996
MacrogolT50.991T50.992T50.993T50.994T50.995T50.996
MethionineT50.991T50.992T50.993T50.994T50.995T50.996
MethoxsalenT50.991T50.992T50.993T50.994T50.995T50.996
5-Methoxypsoralen (5-MOP)T50.991T50.992T50.993T50.994T50.995T50.996
8-Methoxypsoralen (8-MOP)T50.991T50.992T50.993T50.994T50.995T50.996
Methylethyl celluloseT50.991T50.992T50.993T50.994T50.995T50.996
MonooctanoinT50.991T50.992T50.993T50.994T50.995T50.996
OctanoinT50.991T50.992T50.993T50.994T50.995T50.996
OrazamideT50.991T50.992T50.993T50.994T50.995T50.996
Ornithine aspartateT50.991T50.992T50.993T50.994T50.995T50.996
Palm kernel oilT50.991T50.992T50.993T50.994T50.995T50.996
ParathormoneT50.991T50.992T50.993T50.994T50.995T50.996
Parathyroid extractT50.991T50.992T50.993T50.994T50.995T50.996
Phenaphthazine reagentT50.991T50.992T50.993T50.994T50.995T50.996
Protein hydrolysateT50.991T50.992T50.993T50.994T50.995T50.996
Psoralens (medicinal)T50.991T50.992T50.993T50.994T50.995T50.996
SerotoninT50.991T50.992T50.993T50.994T50.995T50.996
SilibininT50.991T50.992T50.993T50.994T50.995T50.996
SilymarinT50.991T50.992T50.993T50.994T50.995T50.996
Teriparatide (acetate)T50.991T50.992T50.993T50.994T50.995T50.996
ThioctamideT50.991T50.992T50.993T50.994T50.995T50.996
Thioctic acidT50.991T50.992T50.993T50.994T50.995T50.996
TidiacicT50.991T50.992T50.993T50.994T50.995T50.996
TioproninT50.991T50.992T50.993T50.994T50.995T50.996
TragacanthT50.991T50.992T50.993T50.994T50.995T50.996
Ursodeoxycholic acidT50.991T50.992T50.993T50.994T50.995T50.996
UrsodiolT50.991T50.992T50.993T50.994T50.995T50.996

Patient Education


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

What is a drug interaction?

A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as gingko and blood thinners
  • Drugs and medical conditions, such as aspirin and peptic ulcers

Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.

What are side effects?

Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.

What are drug allergies?

Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.

How can I stay safe when taking medicines?

When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.